Guardant Health (GH) Sees 48% Growth as Its Cancer Tests Gain Momentum

3 weeks ago 6

Soumya Eswaran

Wed, August 5, 2026 astatine 7:31 AM CDT 3 min read

Baron Capital, an concern absorption company, released its Q2 2026 capitalist missive for the "Baron Health Care Fund". A transcript of the missive is disposable to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% summation for the Russell 3000 Health Care Index and the 15.44% summation for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% connected an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong banal enactment successful pharmaceuticals, biotechnology, wellness attraction equipment, and beingness sciences tools and services supported the Fund's outperformance, though constricted vulnerability to managed attraction stocks reduced comparative returns. The Fund remains affirmative connected wellness attraction owed to improving biotechnology funding, beardown acquisition activity, recovering managed attraction margins, and maturation from an aging population, chronic disease, aesculapian innovation, and higher wellness attraction spending. In addition, delight cheque the Fund's apical 5 holdings to cognize the champion picks successful 2026.

In its second-quarter 2026 capitalist letter, Baron Health Care Fund highlighted Guardant Health, Inc. (NASDAQ:GH). Guardant Health, Inc. (NASDAQ:GH) is simply a US based precision oncology institution that provides humor and insubstantial tests, on with information sets. On August 04, 2026, Guardant Health, Inc. (NASDAQ:GH) closed astatine $159.79 per share. The one-month instrumentality of Guardant Health, Inc. (NASDAQ:GH) was 2.32% and its shares gained 258.35% implicit the past 52 weeks. Guardant Health, Inc. (NASDAQ:GH) has a marketplace capitalization of $21.44 cardinal with a 52-week trading scope betwixt $40.36 - $176.58.

Baron Health Care Fund stated the following regarding Guardant Health, Inc. (NASDAQ:GH) in its Q2 2026 capitalist letter:

"Guardant Health, Inc. (NASDAQ:GH) is simply a specialty diagnostics institution champion known for its blood-based liquid biopsy tests utilized successful crab therapy selection, monitoring, and screening. Shares accrued pursuing beardown first-quarter results, with gross increasing 48% twelvemonth over-year owed to continued adoption of the Guardant360 crab attraction enactment trial and accelerating uptake of the Shield colorectal crab humor test. Guardant360 continues to summation stock wrong the rapidly increasing liquid biopsy market, with momentum accelerating pursuing FDA support of the caller Guardant360 Liquid CDx assay, which should suffice for Advanced Diagnostic Laboratory Test presumption and meaningfully grow mean selling prices. Meanwhile, Shield has the imaginable to thrust meaningful upside arsenic adoption continues to bushed expectations. Notably, the American Cancer Society precocious recommended Shield successful its updated colorectal crab screening guidelines, importantly expanding the imaginable for expanded commercialized security coverage. Looking ahead, we spot Guardant360, Shield, and Reveal (Guardant's crab recurrence monitoring test) positioning the institution to execute affirmative escaped currency travel implicit time."

Read Entire Article